[Summary] Accelerating global biologic drug R&D processes, reducing R&D costs, a
WuXi Biologics (stock code: 2269.HK) is a leading contract research, development, and manufacturing (CRDMO) company. Through an open, integrated biologics capability and technology enabling platform, the company provides comprehensive end-to-end services to help partners discover, develop, and manufacture biologics, achieving the entire process from concept to commercial production, accelerating global biologic drug R&D processes, reducing R&D costs, and benefiting patients worldwide.
Leveraging its global network connecting China, the United States, Ireland, Germany, and Singapore, WuXi Biologics brings together over 13,000 employees, including industry experts and scientists in biologic drug R&D and manufacturing, technological innovation, and operational excellence. With its leading technology platforms and deep expertise, the company provides clients with efficient, cost-effective, and scalable biologic drug solutions, precisely meeting the needs of clients at different stages. In addition, the company systematically integrates digital capabilities and infrastructure into the entire value chain of biologic drug R&D, laboratory operations, and manufacturing, converting data, computing, and predictive capabilities into a more transparent client collaboration experience, faster R&D processes, smarter operational management, and more efficient production delivery. As of the end of December 2025, WuXi Biologics had helped clients develop and manufacture a total of 945 comprehensive projects, including 74 Phase III clinical projects and 25 commercial production projects, with complex molecule projects accounting for more than 50% of the company's total projects.
WuXi Biologics regards sustainable development as the cornerstone of long-term business growth. The company continuously promotes green innovative technologies, providing global partners with advanced end-to-end green CRDMO solutions, while continuously achieving outstanding performance in ESG. Adhering to the concept of creating shared value, the company collaborates with stakeholders to build a sustainable development ecosystem, driving both social value and ecological benefits through responsible operational models, and achieving synergistic empowerment across the entire value chain.
What does Wuxi WuXi Biologics Co., Ltd. require? Who is WuXi Biologics hiring? WuXi Biologics recruitment: 生物/制药/化工/环保类占比最多占33.8%，其次是其他（研发和技术类）占30.2%. What education can get in at WuXi Biologics? 本科占比最多占49%，其次是硕士占19%. High education required at WuXi Biologics? 硕士占19%，博士占5.8%. Work experience required at WuXi Biologics? 不限占比最多占43.3%，其次是1-3年占18.9%. Where are the job locations at WuXi Biologics? 上海占比最多占46.6%，其次是苏州占15.9%. Based on job postings from the past year, for reference only.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
